So thats all to say, in summary, that we do in fact think there is some degree of access, although theres probably more uncertainty around this than there is certainty
Two clinical studies indicated that the mPAP of HAPH patients could normalize after residing at lower altitudes
This diet causes a rapid shift in bacterial flora within one to two weeks
Financial Dominance & Operating Leverage Q3 2025 Financial Highlights Revenue: $17.6B (+54% YoY) Non-GAAP EPS: $7.02 (+495% YoY) Gross Margin: 83.6% (+1.4 pts) Operating Cash: Strong (Record levels) Full-Year 2025 Guidance (Raised) Revenue: $63.0-63.5B (up from $60-62B) Non-GAAP EPS: $23.00-23.70 (up from $21.75-23.00) Profitability Metrics Return on Equity (ROE): ~74-88% (exceptional capital efficiency) Gross Margin: 83.6% (among highest in pharma) R&D Investment: $3.47B in Q3 (+27% YoY) fueling future growth These metrics place Lilly among the most efficient, profitable companies in the S&P 500
CELL-PRESS PLUS RED: Previously offered at $30.00, this product is currently sold out, indicating its popularity among clients
Recent head-to-head clinical trials have directly compared tirzepatide (e.g., Zepbound) to semaglutide (e.g., Wegovy) for weight loss in individuals with obesity but without diabetes
